New combo tackles Hard-to-Treat myeloma

NCT ID NCT05646836

Ongoing Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants will take part, and researchers will also monitor how well the drugs work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Alfred Hospital

Melbourne, Victoria, 3004, Australia
Asan Medical Center - PPDS

Seoul, 05505, South Korea
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Evangelismos General Hospital of Athens

Athens, 106 76, Greece
Hospital Universitari i Politecnic La Fe de Valencia

Valencia, 46026, Spain
Oslo University Hospital Rikshospitalet

Oslo, N - 0424, Norway
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Rabin Medical Center-Beilinson Campus

Petah Tikva, 4941492, Israel
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Severance Hospital, Yonsei University

Seoul, 03722, South Korea
Sygehus Lillebaelt - Vejle Sygehus

Vejle, 7100, Denmark
Tel Aviv Sourasky Medical Center PPDS

Tel Aviv, 64239, Israel
University of Athens, Hematological Clinic,

Athens, 115 28, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.